Market Closed -
Nyse
04:00:02 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
2.68
USD
|
+2.29%
|
|
+3.08%
|
+77.48%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
210.5
|
1,851
|
419.3
|
330.6
|
703.9
|
-
|
-
|
Enterprise Value (EV)
1 |
210.5
|
1,851
|
419.3
|
330.6
|
703.9
|
703.9
|
703.9
|
P/E ratio
|
-50.9
x
|
-19.3
x
|
-4
x
|
-4.31
x
|
-7.58
x
|
-5.33
x
|
-5.36
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
853
x
|
36.5
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
853
x
|
36.5
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
17,988
|
217,788
|
218,393
|
218,944
|
262,636
|
-
|
-
|
Reference price
2 |
11.70
|
8.500
|
1.920
|
1.510
|
2.680
|
2.680
|
2.680
|
Announcement Date
|
3/11/21
|
2/28/22
|
3/15/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
0.8252
|
19.29
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-32.1
|
-43.55
|
-93.32
|
-119.7
|
-99.82
|
-125.4
|
-195.8
|
-189.1
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-23,722.23%
|
-980.43%
|
Earnings before Tax (EBT)
1 |
-
|
-41.66
|
-86.85
|
-104.2
|
-75.8
|
-100.7
|
-162.5
|
-163.6
|
Net income
1 |
-
|
-64.28
|
-86.85
|
-104.2
|
-75.8
|
-100.7
|
-162.5
|
-163.6
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-19,695.46%
|
-848.17%
|
EPS
2 |
-0.1600
|
-0.2300
|
-0.4400
|
-0.4800
|
-0.3500
|
-0.3533
|
-0.5025
|
-0.5000
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/12/20
|
3/11/21
|
2/28/22
|
3/15/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-22.79
|
-29.61
|
-28.19
|
-37.87
|
-29.34
|
-24.34
|
-26.52
|
-26.13
|
-26.34
|
-20.83
|
-27.53
|
-28.83
|
-33.37
|
-35.67
|
-51.1
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-21.98
|
-25.13
|
-21.29
|
-34.86
|
-27.2
|
-20.84
|
-21.73
|
-20.64
|
-19.65
|
-13.79
|
-21.23
|
-22.63
|
-27.44
|
-29.42
|
-44
|
Net income
1 |
-21.98
|
-25.13
|
-21.29
|
-34.86
|
-27.2
|
-20.84
|
-21.73
|
-20.64
|
-19.65
|
-13.79
|
-21.23
|
-22.63
|
-27.44
|
-29.42
|
-44
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.1100
|
-0.1200
|
-0.1000
|
-0.1600
|
-0.1200
|
-0.1000
|
-0.1000
|
-0.0900
|
-0.0900
|
-0.0600
|
-0.0950
|
-0.0783
|
-0.0883
|
-0.0950
|
-0.1100
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/21
|
2/28/22
|
5/9/22
|
8/4/22
|
11/3/22
|
3/15/23
|
5/4/23
|
8/3/23
|
11/2/23
|
2/29/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.15
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/11/21
|
2/28/22
|
3/15/23
|
2/29/24
|
-
|
-
|
-
|
Last Close Price
2.68
USD Average target price
6.6
USD Spread / Average Target +146.27% Consensus |
1st Jan change
|
Capi.
|
---|
| +77.48% | 704M | | +1.51% | 42.75B | | +48.15% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|